| 2.1 -0.1 (-4.55%) | 01-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.96 |
1-year : | 3.39 |
| Resists | First : | 2.53 |
Second : | 2.91 |
| Pivot price | 2.31 |
|||
| Supports | First : | 1.92 |
Second : | 1.6 |
| MAs | MA(5) : | 2.31 |
MA(20) : | 2.35 |
| MA(100) : | 2.28  |
MA(250) : | 2.54 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 25.8 |
D(3) : | 39.3 |
| RSI | RSI(14): 39 |
|||
| 52-week | High : | 3.78 | Low : | 1.73 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SLGC ] has closed above bottom band by 18.6%. Bollinger Bands are 29.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.33 - 2.35 | 2.35 - 2.36 |
| Low: | 1.89 - 1.91 | 1.91 - 1.93 |
| Close: | 2.07 - 2.11 | 2.11 - 2.14 |
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.
Fri, 05 Jan 2024
SomaLogic gains stockholder nod for Standard BioTools deal By Investing.com - Investing.com UK
Thu, 04 Jan 2024
SomaLogic founder, CTO among shareholders opposing Standard BioTools merger - BizWest
Wed, 13 Dec 2023
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ICVX, ROVR, ESMT, SLGC - EIN News
Wed, 04 Oct 2023
SomaLogic to merge with Standard BioTools in all-stock deal - BizWest
Wed, 04 Oct 2023
SomaLogic’s stock surges as it agrees to be bought by Standard BioTools in all-stock merger - MarketWatch
Sun, 11 Jun 2023
Somalogic taps interim CFO, searches for permanent accounting exec - BizWest
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 189 (M) |
| Shares Float | 153 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 61.7 (%) |
| Shares Short | 7,140 (K) |
| Shares Short P.Month | 7,680 (K) |
| EPS | -0.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.63 |
| Profit Margin | -159.6 % |
| Operating Margin | -108.6 % |
| Return on Assets (ttm) | -14.2 % |
| Return on Equity (ttm) | -23.8 % |
| Qtrly Rev. Growth | -47.1 % |
| Gross Profit (p.s.) | -0.06 |
| Sales Per Share | 0.43 |
| EBITDA (p.s.) | -0.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -117 (M) |
| Levered Free Cash Flow | -62 (M) |
| PE Ratio | -3.05 |
| PEG Ratio | 0 |
| Price to Book value | 0.79 |
| Price to Sales | 4.84 |
| Price to Cash Flow | -3.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|